• Health Economics And Outcomes Research
    Health Economics And Outcomes Research
We support bio-pharma companies with real world evidence
and economic modeling to maximize product access and value

Health Economics and Outcomes Research

  • SmartAnalyst utilizes deep disease and domain knowledge to design and deliver successful projects for our clients.
  • We take a holistic approach to Market Access, with the ability to combine patient, payor, and physician insights and work with our clients to develop economic evidence to demonstrate the value of their products.
  • We have developed and utilized innovative methodologies, such as dynamic disease modeling to forecast epidemiology of complex diseases.
Health Economics and Outcomes Research
The SmartAnalyst Difference:
  • Domain expertise in a variety of therapeutic areas, including complex areas such as oncology
  • Data agnostic - ability to employ leading retrospective patient level databases across the globe
  • Flexibility and focus on the client experience - a collaborative working relationship
  • Extensive track record of success with a highly skilled research team
Our capabilities in Health Economics Modeling include:
  • Longitudinal Data Analysis
  • Cost-effectiveness Analysis
  • Risk Sharing Analysis
  • Budget Impact Models
  • Comparative Effectiveness Models
Our capabilities in Health Economics Modeling
Download Recent Publications
NEWS

Our recent publications 

Experimental Hematology and Oncology 2019:

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma - Ravi Potluri, Sandip Ranjan, Hitesh Bhandari, Helen Johnson, Andriy Moshyk and Srividya Kotapati  

ISPOR 2019, May 18-22, New Orleans, LA, USA - Poster Presentation:

Increasing prevalence of depression and the associated risk factors in the US: A study based on NHANES from 2005 to 2016 - Mazumder D, Kaul A, Tyagi R, Potluri R

37th Annual Meeting of the European Society for Paediatric Infectious Diseases, organized jointly by ESPID and the ESPID foundation, May 6-11, 2019, Ljubljana, Slovenia -   Oral Presentation

  • Cumulative incidence of Asthma/Wheezing (AW) among respiratory syncytial virus (RSV) infected infants without high risk factors (HRF) in the Netherlands: A Retrospective Database Analysis  - Bont L, Chéret A, Wyffels V, Diels J, Tyagi R, Mazumder D, Houben E, Smits E, Smulders M, Weber K

  • Health resource utilization (HRU) among infants without high risk factors (HRF) diagnosed with respiratory syncytial virus (RSV) infection in the Netherlands: A Retrospective Database Analysis - Bont L, Chéret A, Wyffels V,  Diels J, Tyagi R, Mazumder D, Houben E, Smits E, Smulders M, Weber K







GLOBAL HEADQUARTERS
(New York, USA)

9 East 38th Street, 8th Floor,
New York 10016
Tel.: (212) 331-0010
Fax: (866) 256-9402

EUROPE
(London, UK)

12 Hammersmith Grove,
London, W6 7AP
Mobile: +44-(0)-752-163-8242
Mobile: +44 (0)-772-574-4296

ASIA PACIFIC
(Gurgaon, INDIA)

14th Floor, Tower D, Cyber Green,
DLF City Phase-III,
Gurgaon 122002, Haryana, India
Tel.: 91-124-4313800